|Videos|November 17, 2017

What Are the Risk Factors for Clostridium difficile Infection?

Richard Haupt, MD, MPH, explains the risk factors for Clostridium difficile infection.

Richard Haupt, MD, MPH, vice president of Medical Development at Pfrizer Vaccines, explains the risk factors for Clostridium difficile infection.

Interview Transcript (modified slightly for readability):

"C. difficile is a bacterium and it exists as a spore, and it exists in the environment; it’s really everywhere. It’s well known and most commonly found in health care settings and, therefore, creates a risk for people who are exposed, or are going to have a health care exposure, but, in fact, the bacteria are everywhere. And we can actually ingest it, and that’s how people acquire C. difficile; it lives in the gut. And then, under certain circumstances, it can actually grow and it can elaborate toxins, and it’s those toxins that actually mediate disease. They kill intestinal cells and that can lead to a severe intestinal illness, and so, that’s what C. difficile is.

The risk factors for C. difficile infection are related mostly to the acquisition of the spores themselves, so, actually, ingesting them and having them and becoming colonized with them, and another risk factors is underlying conditions, underlying comorbidities, people who have disease states that cardiopulmonary disease, diabetes, and other conditions like that. And then, the last, most important, is also antibiotic exposure. Because it’s with the use of antibiotics that a person who has C. difficile spores, those antibiotics can cause a change in the microbiome that allows for C. difficile to actually grow in the gut. And, once that happens, those C. difficile bacteria can elaborate toxins, which can cause intestinal damage.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.